Spots Global Cancer Trial Database for MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Official Title: A Multicentric Phase II Trial Evaluating MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.

Study ID: NCT05888857

Conditions

Advanced Solid Tumor

Interventions

MEDI5752

Study Description

Brief Summary: Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752

Detailed Description: Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752. Patients with mature tertiary lymphoid structures advanced solid tumors will be included in two independent cohorts: * Cohort A: patients with TLS+ IO-naïve solid tumor (miscellaneous) * Cohort B: patients with TLS+ PD1/PDL1-experienced solid tumor (miscellaneous) Each cohort will rely on a two-stage three-outcome design as described in Sargent et al.